📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. (2016)

First Author: Lochhead PA

Attributed to: Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/15384101.2015.1120915

PubMed Identifier: 26959608

Publication URI: http://europepmc.org/abstract/MED/26959608

Type: Journal Article/Review

Volume: 15

Parent Publication: Cell cycle (Georgetown, Tex.)

Issue: 4

ISSN: 1551-4005